N/A N=11 The Role of Cerebellar Hyperactivity in Parkinson's Disease
Parkinson's Disease
Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=150 Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
Depression · Bipolar Disorder · Bipolar Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Change Scores — -15.7; -13.8; -16.0; -15.5 score on a scale — p=.59
N/A N=106 52-104 Week Off-therapy Second Extension to Study CSPP100A2365
Hypertension
Primary: Change in Weight Assessments From Baseline (Visit 2 of the Core Study) to Long Term (LT) Visit 18 (Week 104) for the Enrolled to Follow-up Set (EFS) — 8.90; 9.22 kg…
Phase 1 N=41 A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Advanced Solid Tumors · Adenocarcinoma of the Prostate
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 15; 5; 3 participants
N/A N=55 Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study
Remote Ischemic Preconditioning · Myocardial Protection
Primary: Myocardial Protection Against Ischemic Injury — 298; 231 pg/ml
Phase 3 N=136 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Virus · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Non-inferiority of Arm A to Arm B — 97.8; 93.5 percentage of participants
Phase 4 N=383 A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Herpes Genitalis
Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001
Phase 2 N=150 Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
Bacterial Conjunctivitis
Primary: Change From Baseline Bacterial Culture — 30; 16; 26; 29 cultures — p=0.002
Phase 1 N=56 Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
Healthy Volunteer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 10; 1; 1; 5 Participants
N/A N=66 Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients
Obesity
Primary: Number of Participants Attending 6 Month Follow-up Appointment — 22; 19 Participants
Phase 1 N=43 Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
Proven or Suspected Gram-negative Bacterial Infection · Peri-operative Prophylaxis
Primary: Maximum Plasma Concentration (Cmax) of Ceftolozane — 63.5; 56.2; 51.4; 96.6 μg/mL
Phase 3 N=120 The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery
Bariatric Surgery Candidate
Primary: 0-1 h Postoperative Pain Level — 3.9762; 4.3149 units on a scale
Phase 3 N=275 Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline) — -0.93; 0.21 Percentage (%) — p=<0.0001
N/A N=58 In Home Assessment of Three Anti-Snoring Devices, a Cross Over Study
Snoring
Primary: Bed Partners' Rating of Sleep Disturbance Due to Partner Snoring — 5.0; 3.8; 4.4 units on a scale — p=<.001
Phase 2 N=28 Study of LY2835219 for Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Percentage of Participants Who Achieve Disease Control Rate (DCR) Which Includes Complete Response (CR), Complete Response Unconfirmed (CRu), Partial Response (PR) or…